Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Protein mass spectrum analysis of serum from CKD and NC mice

ABSTRACT: As for serum (CKD vs. NC =4 vs. 4), the protein was extracted by homogenate and SDT lysis. We utilized immunoaffinity depletion of serum high-abundance proteins. Next, we did the following steps: SDS-PAGE separation, Filter-aided sample preparation (FASP Digestion), TMT labeling, peptide fractionation with reversed-phase (RP) chromatography and mass spectrometry analysis. Mass Spectrometry analysis included Easy nLC, LC-MS/MS and data analysis. Differentially expressed proteins between two groups were determined using the t test (the threshold values were set as P < 0.05 and 1.5-fold change).

ORGANISM(S): Mus Musculus

SUBMITTER: Chunlin Gao

PROVIDER: PXD055324 | iProX | Sun Aug 25 00:00:00 BST 2024

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Multiomics Analysis Reveals Therapeutic Targets for Chronic Kidney Disease With Sarcopenia.

Wang Meiqiu M You Lianghui L He Xu X Peng Yingchao Y Wang Ren R Zhang Zhiqiang Z Shu Jiaping J Zhang Pei P Sun Xiaoyi X Jia LiLi L Xia Zhengkun Z Ji Chenbo C Gao Chunlin C

Journal of cachexia, sarcopenia and muscle 20250201 1

<h4>Background</h4>The presence of sarcopenia in patients with chronic kidney disease (CKD) is associated with poor prognosis. The mechanism underlying CKD-induced muscle wasting has not yet been fully explored. This study investigates the influence of renal secretions on muscles using multiomics sequencing.<h4>Methods</h4>The kidney transcriptome analysis by RNA-seq and protein profiling by tandem mass tag (TMT), serum TMT and muscle TMT were performed in CKD established using 0.2% adenine and ...[more]

PMID: 39911133

Similar Datasets

Protein mass spectrum analysis of gastrocnemius from CKD and NC mice

Project description:As for gastrocnemius (CKD vs. NC =4 vs. 4), the protein was extracted by homogenate and SDT lysis. Next, we did the following steps: SDS-PAGE separation, Filter-aided sample preparation (FASP Digestion), TMT labeling, peptide fractionation with reversed-phase (RP) chromatography and mass spectrometry analysis. Mass Spectrometry analysis included Easy nLC, LC-MS/MS and data analysis. Differentially expressed proteins between two groups were determined using the t test (the threshold values were set as P < 0.05 and 1.2-fold change).

2024-08-25 | PXD055326 |

CKD Rats

Project description:CKD Rats

| PRJNA1086545 | ENA

CKD Rats

Project description:Comparative gene expression profiling analysis of RNA-seq data for NC rats, adenine-induced CKD rats, and drug-treated CKD rats.

2024-03-14 | GSE261354 | GEO

Oxalobacter formigenes colonization slows the progression of CKD and reduces cardiac remodeling in CKD

Project description:Accumulation of oxalate in patients with chronic kidney disease (CKD) is associated with CKD progression and an increased risk of cardiac death. Whether reducing oxalate slows CKD progression and prevents cardiovascular complications remains unexplored. We colonized Oxalobacter formigenes (Oxf), an oxalate-degrading microbiome, in the intestines of control and CKD mice fed with 1% hydroxyproline for 23 weeks. RNA-seq analysis of heart tissues of CKD mice reveals dysregulated expression of metabolic pathways and Oxf colonization reverses these changes. These findings demonstrate that oxalate accumulation plays a role not only in CKD progression but also in cardiovascular complications.

2025-06-16 | GSE297087 | GEO

microRNA in chronic kidney disease (CKD)

Project description:microRNA in chronic kidney disease (CKD)

2017-01-01 | GSE80247 | GEO

Expression data from the heart of sham and CKD mice

Project description:High incidence of heart failure (HF) is a typical characteristic of chronic kidney disease (CKD). However, the pathogenesis of CKD-associated HF remains elusive. Here, we investigated the changes in myocardial energy metabolism in CKD mice and explored the underlying mechanisms. To examine genome wide transcriptional changes in the heart of CKD mice, we performed microarray analysis using the Affymetrix Clariom S mouse.

2019-03-16 | GSE126824 | GEO

Quantitative proteomic analysis of CKD urine samples

Project description:Urinary proteomics studies have primarily focused on identifying markers of chronic kidney disease (CKD) progression. Here, we aimed to specify CKD-related injury markers through proteomics analysis in urine of patients with CKD. Label-free quantitative proteomics analysis based on liquid chromatography-tandem mass spectrometry was performed on urine samples obtained from 6, 9, 11, and 10 patients in health control, CKD stage 1, 3 and 5, respectively.

2021-01-19 | PXD016433 | Pride

Iron and kidney macrophages in CKD

Project description:Systemic iron metabolism is disrupted in chronic kidney disease (CKD). However, little is known about local kidney iron homeostasis and its role in kidney fibrosis. Kidney-specific effects of iron therapy in CKD also remain elusive. Here, we elucidate the role of macrophage iron status in kidney fibrosis and demonstrate that it is a potential therapeutic target. In CKD, kidney macrophages exhibited depletion of labile iron pool (LIP) and induction of transferrin receptor 1, indicating intracellular iron deficiency. Low LIP in kidney macrophages was associated with their defective antioxidant response and proinflammatory polarization. Repletion of LIP in kidney macrophages through knockout of ferritin heavy chain (Fth1) reduced oxidative stress and mitigated fibrosis. Similar to Fth1 knockout, iron dextran therapy, through replenishing macrophage LIP, reduced oxidative stress, decreased the production of proinflammatory cytokines, and alleviated kidney fibrosis. Interestingly, iron markedly decreased TGF-β expression and suppressed TGF-β–driven fibrotic response of macrophages. Iron dextran therapy and FtH suppression had an additive protective effect against fibrosis. Adoptive transfer of iron-loaded macrophages alleviated kidney fibrosis, validating the protective effect of iron-replete macrophages in CKD. Thus, targeting intracellular iron deficiency of kidney macrophages in CKD can serve as a therapeutic opportunity to mitigate disease progression.

2023-02-01 | GSE221598 | GEO

Protein mass spectrum analysis of kidney tissue from CKD and NC mice

Project description:Protein mass spectrum analysis of kidney tissue from CKD and NC mice

2024-08-25 | PXD055325 |

Urinary Glycosylated IGF2 peptides in association with CKD

Project description:Chronic kidney disease (CKD) is prevalent in 10% of world’s adult population, with Estimated Glomerular filtration rate (eGFR) and albuminuria employed in diagnosis. Role of protein glycosylation in causal mechanisms of CKD progression is largely unknown. Aim of this study was to identify urinary O-linked glycopeptides in association to CKD for better characterization of CKD molecular manifestations. Urine samples from 2 healthy and 8 CKD subjects were analyzed by CE-MS/MS and glycopeptide analysis using Proteome Discoverer 1.4. Distribution of identi-fied glycopeptides and correlation with Age, eGFR and Albuminuria were evaluated in 3810 da-tasets. In total, 17 O-linked glycopeptides from 7 different proteins were identified, derived primarily from Insulin-like growth factor-II (IGF2). Glycosylation occurred at the surface ex-posed IGF2 Threonine 96 position. Three glycopeptides (DVStPPTVLPDNFPRYPVGKF, DVStPPTVLPDNFPRYPVG and DVStPPTVLPDNFPRYP) exhibited positive correlation with Age. Glycopeptide (tPPTVLPDNFPRYP) showed strong negative association with eGFR. These results suggest that with aging and deteriorating kidney function, alterations in IGF2 proteoforms take place; which may reflect changes in mature IGF2 protein. Our results corroborate this hypothesis as IGF2 increased plasma levels were observed in CKD patients. Protease predictions, consider-ing also available transcriptomics data, suggest activation of cathepsin S with CKD, meriting further investigation.

2023-05-10 | PXD039829 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data